MedTrace Logo

A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer

NCT06623396 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2026-02-11

No results posted yet for this study

Summary

Participants will have a sample of their white blood cells, called T cells, collected using a procedure called leukapheresis. The collected T cells will be sent to a laboratory at Memorial Sloan Kettering to be changed (modified) to become MSLN-targeted CAR T cells, the CAR T-cell therapy that participants will receive during the study. Participant study therapy will take about 3-4 weeks.

Conditions

  • Mesothelin Positive
  • Mesothelin-Expressing Tumors
  • Esophageal Adenocarcinoma
  • Esophageal Adenocarcinomas
  • Esophagogastric Adenocarcinoma
  • Peritoneal Carcinomatosis
  • Breast Neoplasms
  • Diabetes Mellitus

Interventions

BIOLOGICAL

M28z1XXPD1DNR CAR

Participants with esophagastric adenocarcinoma will be treated with an intraperitoneal infusion of different doses of autologous T cells that have been genetically modified ex vivo to express the M28z1XXPD1DNR CAR. The CAR T cells will be manufactured in MSK's Center for Cell Engineering.

Sponsors & Collaborators

Principal Investigators

  • Geoffrey Ku, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-30
Primary Completion
2028-09-30
Completion
2028-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06623396 on ClinicalTrials.gov